The study is a retrospective observational study. The study is designed to be multicentric and international and it will analyze medical records from selected patients diagnosed with locally advanced and resectable NSCLC who underwent lung resection by robotic, VATS and open approach after receiving neoadjuvant chemo-immunotherapy.
There are no risks for the patients, as this is a retrospective data collection.
Diagnosis of clinical or pathological stage IIB (T1-2, hilar N1, M0) and III (any T, N1-2, M0) NSCLC surgically treated with robotic, VATS and open approach with radical intent from 1st of January 2016 to 31st of March 2024
Received neoadjuvant chemo-immunotherapy or immunotherapy alone
Age >= 18 years old at the moment of surgery
Age <18 years old at the moment of surgery
Scientific Institute San Raffaele
Lead sponsor
Memorial Sloan Kettering Cancer Center
Collaborator
Istituto Clinico Humanitas
Collaborator
Regina Elena Cancer Institute
Collaborator
Baptist Health South Florida
Collaborator
West Virginia University
Collaborator